

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability under the Companies Ordinance)

(Stock Code: 00656)

POSITIVE PROFIT ALERT

This announcement is made in accordance with Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board wishes to inform the shareholders of the Company and potential investors that the Consolidated Profit for the year ended 31 December 2009 is expected to increase significantly in comparison with that for the year ended 31 December 2008. The Board considers that the improvement in the performance of the Group is mainly attributable to (i) the fair value gain on certain equity investments held by the Company; and (ii) the share of the gain on deemed disposal of the equity interest in Sinopharm at the time of the listing of the shares of Sinopharm on The Stock Exchange of Hong Kong Limited in September 2009 (in which the Company has an effective equity interest of approximately 16.67% as at 31 December 2009).

Shareholders and investors of the Company are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Fosun International Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) in accordance with Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the preliminary calculations by the senior management of the Company during the course of reviewing the management accounts of the Group for the purpose of compiling the annual results of the Company for the year ended 31 December 2009, the unaudited consolidated profit attributable to equity holders of the Company (the “**Consolidated Profit**”) for the year ended 31 December 2009 is expected to increase significantly in comparison with that for the year ended 31 December 2008.

The board of directors of the Company (the “**Board**”) considers that the improvement in the performance of the Group is mainly attributable to (i) the fair value gain on certain equity investments held by the Company; and (ii) the share of the gain on deemed disposal of the equity interest in Sinopharm Group Co. Ltd. (“**Sinopharm**”) at the time of the listing of the shares of Sinopharm on The Stock Exchange of Hong Kong Limited in September 2009 (in which the Company has an effective equity interest of approximately 16.67% as at 31 December 2009).

The information contained in this announcement is based on the preliminary calculations by the senior management of the Company during the course of reviewing the management accounts of the Group for the purpose of compiling the annual results of the Company for the year ended 31 December 2009. It remains subject to finalisation and necessary adjustments. The annual results of the Group for the year ended 31 December 2009 (the “**2009 Annual Results**”) have not been audited by the auditors of the Company as at the date of this announcement. Detailed financial information of the Company will be disclosed in the 2009 Annual Results and the Company will release its 2009 Annual Results as soon as practicable. Investors are advised to read the 2009 Annual Results with care when it is published.

Shareholders and investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

Shanghai, the PRC, 11 January 2010

As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Fan Wei, Mr. Ding Guoqi, Mr. Qin Xuetao and Mr. Wu Ping; the non-executive director is Mr. Liu Benren; and the independent non-executive directors are Dr. Chen Kaixian, Mr. Zhang Shengman and Mr. Andrew Y. Yan.